# Methoxyamine, Cisplatin, and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors or Mesothelioma That Cannot Be Removed by Surgery or Mesothelioma That Is Refractory to Pemetrexed Disodium and Cisplatin or Carboplatin

> **NCT02535312** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **National Cancer Institute (NCI)** · enrollment: 30 (actual)

## Conditions studied

- Advanced Malignant Solid Neoplasm
- Advanced Peritoneal Malignant Mesothelioma
- Advanced Pleural Malignant Mesothelioma
- Recurrent Peritoneal Malignant Mesothelioma
- Recurrent Pleural Malignant Mesothelioma
- Refractory Malignant Solid Neoplasm
- Unresectable Solid Neoplasm

## Interventions

- **DRUG:** Cisplatin
- **DRUG:** Methoxyamine
- **DRUG:** Pemetrexed Disodium

## Key facts

- **NCT ID:** NCT02535312
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2016-03-08
- **Primary completion:** 2022-12-31
- **Final completion:** 2026-10-15
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2026-04-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02535312

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02535312, "Methoxyamine, Cisplatin, and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors or Mesothelioma That Cannot Be Removed by Surgery or Mesothelioma That Is Refractory to Pemetrexed Disodium and Cisplatin or Carboplatin". Retrieved via MORVS 2026-10-12 from https://api.morvs.ai/clinical/NCT02535312. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*